Kathryn Jenner
Research Subjects
Kathryn Jenner has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Kate Khair
Haemnet Ltd. (United Kingdom)
9 shared publications - Simon Fletcher
University of Oxford
8 shared publications - Mike Holland
Haemnet, London, UK
5 shared publications - Brian O Mahony
Irish Haemophilia Society, Dublin, Ireland
1 shared publication - Declan Noone
European Haemophilia Consortium , Brussels , Belgium
1 shared publication - Flora Peyvandi
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy
1 shared publication
Latest Publications
- Open Access
- 26 October 2026
- Published by Haemnet Ltd in Bleeding Disorders Care & Practice
- p. 57
The Paradox of 'Non-Severe' Haemophilia: Qualitative Analysis of Treatment Disparities and Quality of Life Impacts from the Learning to Live Study
Background: Non-factor replacement therapies and gene therapy for severe haemophilia convert the bleeding phenotype to mild or moderate. People with haemophilia (PwH) who transition to a milder phenotype as a result of their treatment may require a greater degree of ongoing care and support than those with genetically mild or moderate haemophilia, due to previous bleeding episodes. Assessing the subjective experiences of PwH with genetically mild or moderate haemophilia compared to those converted to a milder phenotype enables a comparison of expectations across the spectrum of the disease. Understanding the lived experience of genetically mild and moderate haemophilia can therefore inform the anticipated care needs of the growing group whose treatment converts a severe phenotype to a non-severe one. Methods: Qualitative interviews were undertaken as part of a mixed-methods study examining the lived experience of non-severe haemophilia. Forty-four men with haemophilia (15 mild, 10 moderate, 11 severe, 8 post-gene therapy) aged 16-76 years were interviewed between January and August 2023. Interviews were recorded, transcribed, and thematically analysed using NVivo software, with cross-validation by two researchers. Analysis followed a grounded theory-informed approach. Results: Five main themes emerged within the overarching theme of Ability vs. Disability: 1) Acceptance vs. Rejection, 2) Benefits vs. Burdens, 3) Control vs. Uncertainty, 4) Freedom vs. Constraint, 5) The Future vs. the Past. Participants with genetically non-severe haemophilia reported significant treatment disparities compared to those with severe haemophilia, including delayed diagnosis, inability to self-treat, and limited access to prophylaxis. Despite higher factor levels, individuals with non-severe haemophilia and those who had transitioned to a non-severe phenotype experienced similar issues with regard to bleeding episodes. Paradoxically, while participants reported their condition did not significantly impact daily life, they described constant background concerns about injuries and activity limitations. Conclusions: PwH of all severities experience similar quality of life impacts, particularly during bleeding episodes. Treatment disparities must be addressed to improve outcomes for those with non-severe haemophilia, including individuals on phenotype-altering treatments. Recommendations include facilitating self-infusion and home treatment for all severity levels, ensuring rapid access to bleed assessment and follow-up regardless of primary diagnosis, and addressing the mixed messaging from healthcare teams regarding activity restrictions and treatment protocols.
- 26 October 2026
- Published by Haemnet Ltd in Bleeding Disorders Care & Practice
- p. 57
Open AccessThe Paradox of 'Non-Severe' Haemophilia: Qualitative Analysis of Treatment Disparities and Quality of Life Impacts from the Learning to Live Study
Background: Non-factor replacement therapies and gene therapy for severe haemophilia convert the bleeding phenotype to mild or moderate. People with haemophilia (PwH) who transition to a milder phenotype as a result of their treatment may require a greater degree of ongoing care and support than those with genetically mild or moderate haemophilia, due to previous bleeding episodes. Assessing the subjective experiences of PwH with genetically mild or moderate haemophilia compared to those converted to a milder phenotype enables a comparison of expectations across the spectrum of the disease. Understanding the lived experience of genetically mild and moderate haemophilia can therefore inform the anticipated care needs of the growing group whose treatment converts a severe phenotype to a non-severe one. Methods: Qualitative interviews were undertaken as part of a mixed-methods study examining the lived experience of non-severe haemophilia. Forty-four men with haemophilia (15 mild, 10 moderate, 11 severe, 8 post-gene therapy) aged 16-76 years were interviewed between January and August 2023. Interviews were recorded, transcribed, and thematically analysed using NVivo software, with cross-validation by two researchers. Analysis followed a grounded theory-informed approach. Results: Five main themes emerged within the overarching theme of Ability vs. Disability: 1) Acceptance vs. Rejection, 2) Benefits vs. Burdens, 3) Control vs. Uncertainty, 4) Freedom vs. Constraint, 5) The Future vs. the Past. Participants with genetically non-severe haemophilia reported significant treatment disparities compared to those with severe haemophilia, including delayed diagnosis, inability to self-treat, and limited access to prophylaxis. Despite higher factor levels, individuals with non-severe haemophilia and those who had transitioned to a non-severe phenotype experienced similar issues with regard to bleeding episodes. Paradoxically, while participants reported their condition did not significantly impact daily life, they described constant background concerns about injuries and activity limitations. Conclusions: PwH of all severities experience similar quality of life impacts, particularly during bleeding episodes. Treatment disparities must be addressed to improve outcomes for those with non-severe haemophilia, including individuals on phenotype-altering treatments. Recommendations include facilitating self-infusion and home treatment for all severity levels, ensuring rapid access to bleed assessment and follow-up regardless of primary diagnosis, and addressing the mixed messaging from healthcare teams regarding activity restrictions and treatment protocols.
- Open Access
- 1 January 2025
- Published by Haemnet Ltd in The Journal of Haemophilia Practice
- Vol. 12 (1) , 1-14
“I’d go on a hike with my kids… that would make me feel so happy.” Recognising what people with haemophilia B identify as meaningful when considering personal goals and the potential for gene therapy
Introduction: Historically people with haemophilia B (PwHB) have experienced adverse clinical outcomes including joint bleeds, pain and arthropathy. The current management of severe and moderate haemophilia B in the UK is largely through the use of factor replacement therapy often given as prophylaxis. Despite this, research reveals reduced quality of life (QoL) and psychological burden in PwHB of all severities, highlighting unmet need. Contemporary therapeutic developments including extended half-life factor IX products, novel non-factor agents, and gene therapy offer opportunities to address treatment-related issues and improve QoL. We investigated what PwHB identify as meaningful when considering their personal goals and the potential for gene therapy. Methods: UK men (aged >16 years) with severe or moderate haemophilia B were invited to take part in a face-to-face workshop or one-to-one online audio recorded interview. The recordings were transcribed verbatim, the transcripts were reviewed and coded using a process of inductive thematic analysis. We then used an iterative process to explore, review, reflect, and refine emergent codes and final themes. Ethical approval was not required based on the UK Health Research Authority decision tool. Results: Nine men, all with severe haemophilia B, aged 21 to 64 (median 34 years) participated. All were diagnosed as children; four had a previous family history and all described themselves as ‘well treated’ with self-managed home therapy and prophylaxis. None had received gene therapy. Parallels were observed in their goals. Thematic analysis classified them as achievable, unachievable and future goals. Achievable goals: Achieved despite living with haemophilia B, included education and employment, strong personal relationships, having a family, travelling, having a good social life and being able to participate in sports. Unachievable goals: Things that participants felt unable to achieve either now or in the future. These included changing attitudes of others, a recognition of lost opportunities including more physical, sporting and employment activities. Future goals: Those which might be achieved as treatments evolve. This included being more physically active, improved QoL for affected individuals and their families, greater ability to travel, and optimism for future treatments and their potential impact for future generations. The goals of PwHB often focused on personally meaningful everyday activities. Seemingly modest changes in individual circumstances could impact on QoL and wellbeing. QoL improvements were defined as equitable access to education and employment, increased confidence in undertaking physical activities, and greater ability to travel. Treatment innovations were identified as enhancing individualised patient preferences and reduced fear of bleeding along with its sequelae of pain and limited mobility. Conclusion: With improved access to novel therapeutic options, including gene therapy, PwHB are potentially able to experience equity to people without haemophilia in day-to-day life and activities. This will enable them to reimagine individual goals, their sense of what is ‘achievable’ and live their lives in personally meaningful ways.
- 1 January 2025
- Published by Haemnet Ltd in The Journal of Haemophilia Practice
- Vol. 12 (1) , 1-14
Open Access“I’d go on a hike with my kids… that would make me feel so happy.” Recognising what people with haemophilia B identify as meaningful when considering personal goals and the potential for gene therapy
Introduction: Historically people with haemophilia B (PwHB) have experienced adverse clinical outcomes including joint bleeds, pain and arthropathy. The current management of severe and moderate haemophilia B in the UK is largely through the use of factor replacement therapy often given as prophylaxis. Despite this, research reveals reduced quality of life (QoL) and psychological burden in PwHB of all severities, highlighting unmet need. Contemporary therapeutic developments including extended half-life factor IX products, novel non-factor agents, and gene therapy offer opportunities to address treatment-related issues and improve QoL. We investigated what PwHB identify as meaningful when considering their personal goals and the potential for gene therapy. Methods: UK men (aged >16 years) with severe or moderate haemophilia B were invited to take part in a face-to-face workshop or one-to-one online audio recorded interview. The recordings were transcribed verbatim, the transcripts were reviewed and coded using a process of inductive thematic analysis. We then used an iterative process to explore, review, reflect, and refine emergent codes and final themes. Ethical approval was not required based on the UK Health Research Authority decision tool. Results: Nine men, all with severe haemophilia B, aged 21 to 64 (median 34 years) participated. All were diagnosed as children; four had a previous family history and all described themselves as ‘well treated’ with self-managed home therapy and prophylaxis. None had received gene therapy. Parallels were observed in their goals. Thematic analysis classified them as achievable, unachievable and future goals. Achievable goals: Achieved despite living with haemophilia B, included education and employment, strong personal relationships, having a family, travelling, having a good social life and being able to participate in sports. Unachievable goals: Things that participants felt unable to achieve either now or in the future. These included changing attitudes of others, a recognition of lost opportunities including more physical, sporting and employment activities. Future goals: Those which might be achieved as treatments evolve. This included being more physically active, improved QoL for affected individuals and their families, greater ability to travel, and optimism for future treatments and their potential impact for future generations. The goals of PwHB often focused on personally meaningful everyday activities. Seemingly modest changes in individual circumstances could impact on QoL and wellbeing. QoL improvements were defined as equitable access to education and employment, increased confidence in undertaking physical activities, and greater ability to travel. Treatment innovations were identified as enhancing individualised patient preferences and reduced fear of bleeding along with its sequelae of pain and limited mobility. Conclusion: With improved access to novel therapeutic options, including gene therapy, PwHB are potentially able to experience equity to people without haemophilia in day-to-day life and activities. This will enable them to reimagine individual goals, their sense of what is ‘achievable’ and live their lives in personally meaningful ways.
- Open Access
- 15 November 2024
- Published by Wiley in Haemophilia
- Vol. 30 (6) , 1373-1382
One day at a time: Life with Glanzmann thrombasthenia – Qualitative results from the GT 360 study
Introduction: Glanzmann thrombasthenia (GT) is a platelet function disorder. Symptoms include bruising and bleeding, which may be severe and life‐threatening. The day‐to‐day experiences of those affected remain poorly documented.Aims: The Glanzmann's 360 study aimed to better understand the daily realities of living with GT, exploring psychological, social and medical challenges to identify unmet need.Methods: People with GT over 18 and caregivers of children with GT participated. Mixed methods research was used, including a survey and in‐depth interviews. The interviews, reported here, were audio‐recorded, transcribed and thematically analysed.Results: Nineteen interviews were conducted; 14 with people with GT and five caregivers. Mean age of those with GT was 32.9 years (range 2–78 years). Eight themes emerged: Diagnosis, Bleeding and Treatment, Menstruation, Fatigue, Identity, Abuse, Pregnancy, and The Future. Three participants described misdiagnosis. Caregivers reported early recognition and prompt diagnosis of their children. Bruising, the most commonly reported symptom, led to assumption of abuse. Six (32%) participants reported joint bleeds. External bleeding was normalised. Access to home treatment and local care were limited. Fatigue caused by anaemia was described. All women reported heavy menstrual bleeding. Choices around pregnancy were limited by ‘medical pessimism’. Nevertheless, participants remained hopeful for the development of improved treatment options.Conclusion: People with GT face significant and often overlooked challenges. There is need for improved medical and psychological treatment and support, increased awareness of these needs amongst healthcare professionals, and research into developing comprehensive care models that address medical and psychosocial needs of people with GT.
- 15 November 2024
- Published by Wiley in Haemophilia
- Vol. 30 (6) , 1373-1382
Open AccessOne day at a time: Life with Glanzmann thrombasthenia – Qualitative results from the GT 360 study
Introduction: Glanzmann thrombasthenia (GT) is a platelet function disorder. Symptoms include bruising and bleeding, which may be severe and life‐threatening. The day‐to‐day experiences of those affected remain poorly documented.Aims: The Glanzmann's 360 study aimed to better understand the daily realities of living with GT, exploring psychological, social and medical challenges to identify unmet need.Methods: People with GT over 18 and caregivers of children with GT participated. Mixed methods research was used, including a survey and in‐depth interviews. The interviews, reported here, were audio‐recorded, transcribed and thematically analysed.Results: Nineteen interviews were conducted; 14 with people with GT and five caregivers. Mean age of those with GT was 32.9 years (range 2–78 years). Eight themes emerged: Diagnosis, Bleeding and Treatment, Menstruation, Fatigue, Identity, Abuse, Pregnancy, and The Future. Three participants described misdiagnosis. Caregivers reported early recognition and prompt diagnosis of their children. Bruising, the most commonly reported symptom, led to assumption of abuse. Six (32%) participants reported joint bleeds. External bleeding was normalised. Access to home treatment and local care were limited. Fatigue caused by anaemia was described. All women reported heavy menstrual bleeding. Choices around pregnancy were limited by ‘medical pessimism’. Nevertheless, participants remained hopeful for the development of improved treatment options.Conclusion: People with GT face significant and often overlooked challenges. There is need for improved medical and psychological treatment and support, increased awareness of these needs amongst healthcare professionals, and research into developing comprehensive care models that address medical and psychosocial needs of people with GT.
- Open Access
- 10 February 2024
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 19 (1) , 1-12
Barriers to gene therapy, understanding the concerns people with haemophilia have: an exigency sub-study
Background: Gene therapy has the potential to offer people with haemophilia (PwH) a life free from bleeding and the burden posed by current treatment regimens. To date, gene therapy has only been available in clinical trial settings, to PwH without pre-existing or historical factor inhibitors, significant concomitant liver damage or pre-existing neutralising antibodies to the adeno-associated viruses used to deliver the therapy. Thus, most PwH treated at centres not currently involved in gene therapy trials, either as a referral/follow-up centre or as a dosing centre, have been unable to access the therapy. This Exigency sub-study aims to gain a greater understanding of the opinions of PwH in the United Kingdom who have not had access to gene therapy: asking what they understand, what concerns they have, and whether they perceive any barriers preventing their access to gene therapy. Results: Twenty-three PwH were approached; 14 consented, and one withdrew prior to interview. The mean age of the participants was 35.7 years (range 25–74 years). Eleven had haemophilia A and two haemophilia B. Two were treated with standard half-life factor products, five with extended half-life products, five with a FVIII mimetic and one with a clinical trial product. One family member (a participant's partner) was also interviewed. The participants identified four barriers to gene therapy: concerns about the process of gene therapy (Expectations), uncertainty about the results (outcomes), (Access) to treatment, and a lack of understanding about gene therapy (education). Conclusions: This Exigency study subgroup sees gene therapy as a positive treatment development that promises an improved quality of life. For this participant group, four issues impact their decision to undergo gene therapy. If the promise of gene therapy is to be realised, these barriers need to be acknowledged and addressed by healthcare professionals, patient organisations, and gene therapy providers.
- 10 February 2024
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 19 (1) , 1-12
Open AccessBarriers to gene therapy, understanding the concerns people with haemophilia have: an exigency sub-study
Background: Gene therapy has the potential to offer people with haemophilia (PwH) a life free from bleeding and the burden posed by current treatment regimens. To date, gene therapy has only been available in clinical trial settings, to PwH without pre-existing or historical factor inhibitors, significant concomitant liver damage or pre-existing neutralising antibodies to the adeno-associated viruses used to deliver the therapy. Thus, most PwH treated at centres not currently involved in gene therapy trials, either as a referral/follow-up centre or as a dosing centre, have been unable to access the therapy. This Exigency sub-study aims to gain a greater understanding of the opinions of PwH in the United Kingdom who have not had access to gene therapy: asking what they understand, what concerns they have, and whether they perceive any barriers preventing their access to gene therapy. Results: Twenty-three PwH were approached; 14 consented, and one withdrew prior to interview. The mean age of the participants was 35.7 years (range 25–74 years). Eleven had haemophilia A and two haemophilia B. Two were treated with standard half-life factor products, five with extended half-life products, five with a FVIII mimetic and one with a clinical trial product. One family member (a participant's partner) was also interviewed. The participants identified four barriers to gene therapy: concerns about the process of gene therapy (Expectations), uncertainty about the results (outcomes), (Access) to treatment, and a lack of understanding about gene therapy (education). Conclusions: This Exigency study subgroup sees gene therapy as a positive treatment development that promises an improved quality of life. For this participant group, four issues impact their decision to undergo gene therapy. If the promise of gene therapy is to be realised, these barriers need to be acknowledged and addressed by healthcare professionals, patient organisations, and gene therapy providers.
- Open Access
- 1 January 2023
- Published by Haemnet Ltd in The Journal of Haemophilia Practice
- Vol. 10 (1) , 62-67
Shared decision-making for gene therapy in haemophilia care
Shared decision-making (SDM) is an important part of patient-centred care in which healthcare professionals (HCPs) and patients/caregivers jointly reach care decisions through a two-way exchange and synthesis of information based on clinical evidence and patient preference. SDM was described in haemophilia care in 2014 as two-sided intervention to aid patient decision-making. However, as the range of haemophilia treatments has expanded, identifying the optimal haemophilia treatment for an individual has become more complex. This is particularly so in the case of gene therapy, a onetime-only, irreversible treatment. In this context, it is vital that people with haemophilia (PwH) and their families continue to be involved in care decisions in an informed and interactive way. For gene therapy, this must include being well informed about the gene therapy process, enabling the patient to engage in fully informed SDM and consent, and ensuring that issues around long-term durability, potential side effects, the need for long-term follow-up are understood with a recognition that the ‘unknown unknowns’ are also unknown to HCPs. Both HCPs and patient organisations have a key role to play in providing PwH with access to relevant information and education, tailored to individual needs and free of jargon. Considerable education and support are required before PwH can make a truly informed decision about having gene therapy. Use of structured SDM tools such as the SHARE approach can help to support this. There is a need for SDM educational tools that include written/visual information and the use of standardised checklists may be helpful for both PwH and HCPs. The most important part of this process is that PwH want to undergo gene therapy – and this is only an option if they are fully educated and informed by fully educated and informed healthcare teams.
- 1 January 2023
- Published by Haemnet Ltd in The Journal of Haemophilia Practice
- Vol. 10 (1) , 62-67
Open AccessShared decision-making for gene therapy in haemophilia care
Shared decision-making (SDM) is an important part of patient-centred care in which healthcare professionals (HCPs) and patients/caregivers jointly reach care decisions through a two-way exchange and synthesis of information based on clinical evidence and patient preference. SDM was described in haemophilia care in 2014 as two-sided intervention to aid patient decision-making. However, as the range of haemophilia treatments has expanded, identifying the optimal haemophilia treatment for an individual has become more complex. This is particularly so in the case of gene therapy, a onetime-only, irreversible treatment. In this context, it is vital that people with haemophilia (PwH) and their families continue to be involved in care decisions in an informed and interactive way. For gene therapy, this must include being well informed about the gene therapy process, enabling the patient to engage in fully informed SDM and consent, and ensuring that issues around long-term durability, potential side effects, the need for long-term follow-up are understood with a recognition that the ‘unknown unknowns’ are also unknown to HCPs. Both HCPs and patient organisations have a key role to play in providing PwH with access to relevant information and education, tailored to individual needs and free of jargon. Considerable education and support are required before PwH can make a truly informed decision about having gene therapy. Use of structured SDM tools such as the SHARE approach can help to support this. There is a need for SDM educational tools that include written/visual information and the use of standardised checklists may be helpful for both PwH and HCPs. The most important part of this process is that PwH want to undergo gene therapy – and this is only an option if they are fully educated and informed by fully educated and informed healthcare teams.
- Open Access
- 4 April 2022
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 17 (1) , 1-9
The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the Exigency study
Background: Gene therapy has the potential to change the life experience of people with haemophilia and family members. Few studies have sought to explore the impact of gene therapy on both individuals and families. The aim of this study was to capture real-life experiences of gene therapy in People with haemophilia and their families.Results: Sixteen participants with severe haemophilia (11 haemophilia A, five haemophilia B), mean age 41.4 years (range 23–75 years), took part in a single qualitative interview; ten were accompanied by a family member. Mean time since transfection was 3.56 years (range 1–10 years). Participants saw their involvement in gene therapy as a positive experience, freeing them from the personal burden of haemophilia and furthering treatment options for the wider haemophilia community. However, participants reported being unprepared for the side effects of immunosuppression. Some also reported feeling unsupported and having little control over what was happening as their factor levels became the focus of the process.Conclusion: The results suggest that strategies need to be put into place to enable PwH fully to understand the process of gene therapy, and thereby make an informed choice as to whether it is a treatment they might wish for themselves. These include early and ongoing education, increased provision of psychosocial support and ongoing qualitative research.
- 4 April 2022
- Published by Springer Nature in Orphanet Journal of Rare Diseases
- Vol. 17 (1) , 1-9
Open AccessThe experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the Exigency study
Background: Gene therapy has the potential to change the life experience of people with haemophilia and family members. Few studies have sought to explore the impact of gene therapy on both individuals and families. The aim of this study was to capture real-life experiences of gene therapy in People with haemophilia and their families.Results: Sixteen participants with severe haemophilia (11 haemophilia A, five haemophilia B), mean age 41.4 years (range 23–75 years), took part in a single qualitative interview; ten were accompanied by a family member. Mean time since transfection was 3.56 years (range 1–10 years). Participants saw their involvement in gene therapy as a positive experience, freeing them from the personal burden of haemophilia and furthering treatment options for the wider haemophilia community. However, participants reported being unprepared for the side effects of immunosuppression. Some also reported feeling unsupported and having little control over what was happening as their factor levels became the focus of the process.Conclusion: The results suggest that strategies need to be put into place to enable PwH fully to understand the process of gene therapy, and thereby make an informed choice as to whether it is a treatment they might wish for themselves. These include early and ongoing education, increased provision of psychosocial support and ongoing qualitative research.
- Open Access
- 1 January 2022
- Published by Haemnet Ltd in The Journal of Haemophilia Practice
- Vol. 9 (1) , 156-166
The journey of gene therapy in haemophilia – putting the patient at the centre of the hub and spoke model
As gene therapy for haemophilia is now licensed in Europe, and the hub and spoke approach is widely promoted for its delivery and follow-up, it is essential that people with haemophilia (PwH) who are eligible and opt to have this treatment are enabled to obtain the maximum benefit. Ensuring the pathway that makes up the patient gene therapy journey is effective is key to achieving this. EAHAD and the EHC have recommended that gene therapy is delivered through a hub and spoke model of care to ensure that the right expertise is available throughout the various stages of the haemophilia gene therapy journey. Effective communication between hub and spoke centres is essential, and the processes that make up the journey must be understood clearly by both PwH and the multidisciplinary teams delivering their care. The starting point for this is to take each step of the gene therapy journey in turn – through initial engagement, eligibility, detailed patient education, informed decision-making, dosing, and follow up in year 1, year 2 and beyond – and to consider and identify the roles and responsibilities of the patient, the hub centre and the spoke centre. It is important that the expectations of both health care practitioners (HCPs) and patients are aligned with the key challenges and goals associated with each step. Understanding these from the patient point of view will help to ensure that the individual PwH treading this path receive the information, guidance and support they need from hub and spoke HCPs throughout their journey, and that they, as the patient, remain the focus of care. Visualising the journey may help to explain the gene therapy clinical pathway to PwH and could provide a useful tool for HCPs in spoke centres. Visualisation may also serve as a tool for facilitating discussion, not only in terms of initial engagement and education, but throughout the haemophilia gene therapy journey.
- 1 January 2022
- Published by Haemnet Ltd in The Journal of Haemophilia Practice
- Vol. 9 (1) , 156-166
Open AccessThe journey of gene therapy in haemophilia – putting the patient at the centre of the hub and spoke model
As gene therapy for haemophilia is now licensed in Europe, and the hub and spoke approach is widely promoted for its delivery and follow-up, it is essential that people with haemophilia (PwH) who are eligible and opt to have this treatment are enabled to obtain the maximum benefit. Ensuring the pathway that makes up the patient gene therapy journey is effective is key to achieving this. EAHAD and the EHC have recommended that gene therapy is delivered through a hub and spoke model of care to ensure that the right expertise is available throughout the various stages of the haemophilia gene therapy journey. Effective communication between hub and spoke centres is essential, and the processes that make up the journey must be understood clearly by both PwH and the multidisciplinary teams delivering their care. The starting point for this is to take each step of the gene therapy journey in turn – through initial engagement, eligibility, detailed patient education, informed decision-making, dosing, and follow up in year 1, year 2 and beyond – and to consider and identify the roles and responsibilities of the patient, the hub centre and the spoke centre. It is important that the expectations of both health care practitioners (HCPs) and patients are aligned with the key challenges and goals associated with each step. Understanding these from the patient point of view will help to ensure that the individual PwH treading this path receive the information, guidance and support they need from hub and spoke HCPs throughout their journey, and that they, as the patient, remain the focus of care. Visualising the journey may help to explain the gene therapy clinical pathway to PwH and could provide a useful tool for HCPs in spoke centres. Visualisation may also serve as a tool for facilitating discussion, not only in terms of initial engagement and education, but throughout the haemophilia gene therapy journey.
- Open Access
- 8 December 2021
- Published by Wiley in Health Expectations
- Vol. 25 (1) , 443-454
The lived experience of a novel disruptive therapy in a group of men and boys with haemophilia A with inhibitors: Emi & Me
Background: People with haemophilia A and inhibitors (PwHi) suffer more orthopaedic complications, bleeding and pain than those without inhibitors. The advent of emicizumab as a prophylactic treatment has led to a reduction in bleed frequency and a significant improvement in overall quality of life. No research to date has examined the nature of this improvement on treated individuals and their families.Aims: The Emi & Me study aims to capture the real‐life experience of using emicizumab for PwHi and their families.Methods: Participants were recruited through treatment centres, social media and by word of mouth. Each participant and a family member, if available, took part in a semistructured qualitative interview. All interviews were recorded, transcribed verbatim and analysed thematically. All elements of the study were reviewed by local statutory authorities and informed consent was sought from all participants.Results: Fifteen PwHi, mean age 27.2 years (range 8–63 years), most with a family member, participated in a single qualitative interview online (n = 13), by telephone (n = 1) or in person (n = 1). Mean time on emicizumab was 2.26 years (range 1–5 years). Six major themes emerged: bleeds; pain; treatment burden; control; freedom (for both PwHi and family members) and missed potential. Emicizumab prophylaxis has delivered significant improvements in the lives of the participants. Despite these improvements, some participants felt that their pre‐existing physical disabilities and the lack of physiotherapy provision had prevented them achieving similar improvements in their functional ability.Conclusion: This study shows that in reducing bleeds, pain and treatment burden, emicizumab had given PwHi greater control over their condition, allowing a sense of freedom they had not experienced with factor VIII or bypassing agent prophylaxis. However, for emicizumab to be truly effective, there is a need to ensure the continued availability and accessibility of robust multidisciplinary support services. Without this, it is unlikely that PwHi will realize the life‐changing potential offered either by emicizumab or any other novel treatment approach.Patient or Public Contribution: A patient participant (who did not wish to be included as an author of the paper) was involved in the design of the study protocol and interview guide.
- 8 December 2021
- Published by Wiley in Health Expectations
- Vol. 25 (1) , 443-454
Open AccessThe lived experience of a novel disruptive therapy in a group of men and boys with haemophilia A with inhibitors: Emi & Me
Background: People with haemophilia A and inhibitors (PwHi) suffer more orthopaedic complications, bleeding and pain than those without inhibitors. The advent of emicizumab as a prophylactic treatment has led to a reduction in bleed frequency and a significant improvement in overall quality of life. No research to date has examined the nature of this improvement on treated individuals and their families.Aims: The Emi & Me study aims to capture the real‐life experience of using emicizumab for PwHi and their families.Methods: Participants were recruited through treatment centres, social media and by word of mouth. Each participant and a family member, if available, took part in a semistructured qualitative interview. All interviews were recorded, transcribed verbatim and analysed thematically. All elements of the study were reviewed by local statutory authorities and informed consent was sought from all participants.Results: Fifteen PwHi, mean age 27.2 years (range 8–63 years), most with a family member, participated in a single qualitative interview online (n = 13), by telephone (n = 1) or in person (n = 1). Mean time on emicizumab was 2.26 years (range 1–5 years). Six major themes emerged: bleeds; pain; treatment burden; control; freedom (for both PwHi and family members) and missed potential. Emicizumab prophylaxis has delivered significant improvements in the lives of the participants. Despite these improvements, some participants felt that their pre‐existing physical disabilities and the lack of physiotherapy provision had prevented them achieving similar improvements in their functional ability.Conclusion: This study shows that in reducing bleeds, pain and treatment burden, emicizumab had given PwHi greater control over their condition, allowing a sense of freedom they had not experienced with factor VIII or bypassing agent prophylaxis. However, for emicizumab to be truly effective, there is a need to ensure the continued availability and accessibility of robust multidisciplinary support services. Without this, it is unlikely that PwHi will realize the life‐changing potential offered either by emicizumab or any other novel treatment approach.Patient or Public Contribution: A patient participant (who did not wish to be included as an author of the paper) was involved in the design of the study protocol and interview guide.
- 20 November 2020
- Published by Wiley in Haemophilia
- Vol. 27 (1) , 120-128
Parental perspectives on gene therapy for children with haemophilia: The Exigency study
Introduction Gene therapy is used in life‐limiting conditions of childhood. While not a current therapeutic option for children with haemophilia, it may be considered in the future especially for those where access to treatment is limited. Aim To assess the attitudes and opinions of parents of children with haemophilia about gene therapy as a potential future treatment, by understanding their awareness about gene therapy and what they need to know now and in the future; gauging levels of interest in gene therapy for their children; and exploring perceived current motivations and barriers. Methods A mixed methods study with an online questionnaire and in‐depth qualitative interviews in focus groups which were analysed using thematic analysis. Results One hundred and fifty‐eight participants commenced the online survey; 63 were fully completed (39%). 60 had heard of gene therapy but few (17/60 [28.3%]) felt they had a good understanding. 38/60 (63.3%) respondents did not know that gene therapy is not available for children. However, most held positive views: 53/60 (88.3%) saying they would consider it for their child. In the interviews, participants (N = 10, all mothers) discussed their awareness and understanding of gene therapy and opinions about it for children, including how this should be communicated to the child and parents. Conclusion A coherent, community‐wide strategy for communicating information and news about gene therapy should now be provided for children and families living with haemophilia. This should come primarily from trusted haemophilia nursing teams, who can give tailored, age‐appropriate, factual advice.
- 20 November 2020
- Published by Wiley in Haemophilia
- Vol. 27 (1) , 120-128
Parental perspectives on gene therapy for children with haemophilia: The Exigency study
Introduction Gene therapy is used in life‐limiting conditions of childhood. While not a current therapeutic option for children with haemophilia, it may be considered in the future especially for those where access to treatment is limited. Aim To assess the attitudes and opinions of parents of children with haemophilia about gene therapy as a potential future treatment, by understanding their awareness about gene therapy and what they need to know now and in the future; gauging levels of interest in gene therapy for their children; and exploring perceived current motivations and barriers. Methods A mixed methods study with an online questionnaire and in‐depth qualitative interviews in focus groups which were analysed using thematic analysis. Results One hundred and fifty‐eight participants commenced the online survey; 63 were fully completed (39%). 60 had heard of gene therapy but few (17/60 [28.3%]) felt they had a good understanding. 38/60 (63.3%) respondents did not know that gene therapy is not available for children. However, most held positive views: 53/60 (88.3%) saying they would consider it for their child. In the interviews, participants (N = 10, all mothers) discussed their awareness and understanding of gene therapy and opinions about it for children, including how this should be communicated to the child and parents. Conclusion A coherent, community‐wide strategy for communicating information and news about gene therapy should now be provided for children and families living with haemophilia. This should come primarily from trusted haemophilia nursing teams, who can give tailored, age‐appropriate, factual advice.